JP2015526463A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015526463A5 JP2015526463A5 JP2015528010A JP2015528010A JP2015526463A5 JP 2015526463 A5 JP2015526463 A5 JP 2015526463A5 JP 2015528010 A JP2015528010 A JP 2015528010A JP 2015528010 A JP2015528010 A JP 2015528010A JP 2015526463 A5 JP2015526463 A5 JP 2015526463A5
- Authority
- JP
- Japan
- Prior art keywords
- daptomycin
- tocopheryl phosphate
- tpm
- formulation
- lyophilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2452/MUM/2012 | 2012-08-23 | ||
| IN2452MU2012 | 2012-08-23 | ||
| PCT/IN2013/000511 WO2014045296A2 (en) | 2012-08-23 | 2013-08-22 | Improved daptomycin injectable formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015526463A JP2015526463A (ja) | 2015-09-10 |
| JP2015526463A5 true JP2015526463A5 (enExample) | 2016-10-06 |
Family
ID=54187094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015528010A Pending JP2015526463A (ja) | 2012-08-23 | 2013-08-22 | 改善されたダプトマイシン注射用製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150216928A1 (enExample) |
| EP (2) | EP3287138A1 (enExample) |
| JP (1) | JP2015526463A (enExample) |
| AU (2) | AU2013319737B2 (enExample) |
| BR (1) | BR112015003198A2 (enExample) |
| CA (1) | CA2881121A1 (enExample) |
| DK (1) | DK2887953T3 (enExample) |
| ES (1) | ES2655215T3 (enExample) |
| NO (1) | NO2887953T3 (enExample) |
| PT (1) | PT2887953T (enExample) |
| SI (1) | SI2887953T1 (enExample) |
| WO (1) | WO2014045296A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE13837694T1 (de) | 2012-09-11 | 2015-12-31 | Hospira Australia Pty Ltd. | Daptomycinformulierungen und Verwendungen davon |
| WO2018073269A1 (en) | 2016-10-21 | 2018-04-26 | Xellia Pharmaceuticals Aps | Liquid formulations of daptomycin |
| MX2020001885A (es) | 2017-08-31 | 2020-09-07 | Xellia Pharmaceuticals Aps | Formulaciones de daptomicina. |
| CA3170514A1 (en) | 2020-03-12 | 2021-09-16 | Baxter International Inc. | Daptomycin formulations containing a combination of sorbitol and mannitol |
| CN112684043A (zh) * | 2020-12-16 | 2021-04-20 | 南京健友生化制药股份有限公司 | 一种达托霉素有关物质的检测方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4537717A (en) | 1982-05-21 | 1985-08-27 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| FR2657526B1 (fr) * | 1990-01-31 | 1994-10-28 | Lvmh Rech | Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues. |
| WO1997014705A1 (fr) * | 1995-10-17 | 1997-04-24 | Showa Denko K.K. | Phosphates de tocopherol tres purs, procedes de preparation, techniques d'analyse et produits cosmetiques correspondants |
| JP4088597B2 (ja) * | 2004-01-06 | 2008-05-21 | 樹男 飯田 | 内服および注射用組成物とその製法 |
| US20080032384A1 (en) * | 2004-04-22 | 2008-02-07 | Takehiko Nomura | Pharmaceutical Preparation Containing Bacterial Cell Wall Skeleton |
| CA2611831C (en) * | 2005-06-17 | 2014-09-16 | Vital Health Sciences Pty Ltd. | A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
| CA2772660A1 (en) * | 2009-09-01 | 2011-03-10 | Northwestern University | Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers |
| US8431539B2 (en) * | 2009-09-17 | 2013-04-30 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
| BR112012012406B1 (pt) * | 2009-11-23 | 2021-11-16 | Cubist Pharmaceuticals Llc | Composições farmacêuticas sólidas de daptomicina, seu produto farmacêutico e seus métodos de fabricação |
| AU2011213557B2 (en) * | 2010-02-05 | 2015-05-07 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
| CA2752784A1 (en) * | 2010-09-21 | 2012-03-21 | Xellia Pharmaceuticals Aps | Daptomycin formulation |
-
2013
- 2013-08-22 CA CA2881121A patent/CA2881121A1/en not_active Abandoned
- 2013-08-22 EP EP17194652.8A patent/EP3287138A1/en not_active Withdrawn
- 2013-08-22 JP JP2015528010A patent/JP2015526463A/ja active Pending
- 2013-08-22 AU AU2013319737A patent/AU2013319737B2/en not_active Ceased
- 2013-08-22 SI SI201330908T patent/SI2887953T1/en unknown
- 2013-08-22 US US14/431,170 patent/US20150216928A1/en not_active Abandoned
- 2013-08-22 BR BR112015003198A patent/BR112015003198A2/pt not_active Application Discontinuation
- 2013-08-22 WO PCT/IN2013/000511 patent/WO2014045296A2/en not_active Ceased
- 2013-08-22 ES ES13838871.5T patent/ES2655215T3/es active Active
- 2013-08-22 PT PT138388715T patent/PT2887953T/pt unknown
- 2013-08-22 EP EP13838871.5A patent/EP2887953B1/en not_active Not-in-force
- 2013-08-22 DK DK13838871.5T patent/DK2887953T3/en active
- 2013-08-22 NO NO13838871A patent/NO2887953T3/no unknown
-
2018
- 2018-06-18 AU AU2018204334A patent/AU2018204334A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015526463A5 (enExample) | ||
| HRP20200072T1 (hr) | Načini doziranja za spojeve klase ehinokandina | |
| AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
| BR112013003045A2 (pt) | composto e composição farmacêutica e respectivos usos, recipiente estéril e método para preparar composição farmacêutica para administração | |
| MX389346B (es) | Formulaciones de anticuerpos monoclonales de alta concentración. | |
| EA200901128A1 (ru) | Твердый фармацевтический препарат и вакцинная доза | |
| NZ700182A (en) | Parenteral formulations for administering macrolide antibiotics | |
| MX340985B (es) | Compuestos de n-heteroarilo. | |
| FI3685847T3 (fi) | Komplementtiaktiivisuuden modulaattoreita | |
| UA117480C2 (uk) | Лікування цукрового діабету за допомогою складу інсуліну тривалої дії | |
| EP4218769A3 (en) | Treatment of oculopharyngeal muscular dystrophy by intravenous administration of trehalose | |
| EA201691490A1 (ru) | Фармацевтическая композиция, содержащая бринзоламид | |
| MX2017000764A (es) | Formulacion acuosa que comprende paracetamol e ibuprofeno. | |
| EA201592040A1 (ru) | Иммуногенная композиция для применения в терапии | |
| SI2887953T1 (en) | IMPROVED DAPTOMICINE FORMATION FORMULATION | |
| BR112016025481A2 (pt) | alimentos, sistemas, métodos e estojos para provisão de substituição de eletrólito | |
| WO2016040814A3 (en) | Disulfide polymers and methods of use | |
| MY184630A (en) | Tylosin derivatives and method for preparation thereof | |
| RU2017144216A (ru) | Антибактериальные композиции | |
| JP2014504613A5 (enExample) | ||
| RU2015145451A (ru) | Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол | |
| WO2014145713A3 (en) | Aminoglycoside antibiotics with reduced ototoxicity | |
| UA115333C2 (uk) | Склад есмололу для парентерального введення | |
| RU2016101248A (ru) | Лиофилизированные препараты бендамустина гидрохлорида | |
| WO2011126327A3 (en) | Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof |